Study finds similar six-month weight loss on 2.5 mg and 5 mg tirzepatide

A six-month study of 112 non-diabetic Japanese adults with obesity found that staying on a 2.5 mg weekly dose of tirzepatide produced nearly the same weight loss as increasing to 5 mg, with fewer side effects at the lower dose. The study was published July 28, 2026, in the journal Diabetes, Obesity and Metabolism ^[1].

The work is a multicenter, prospective cohort, not a randomized trial. Participants were 18 to 65 years old with a body mass index of 30 or higher, or 27 or higher with related conditions. Everyone began tirzepatide at 2.5 mg weekly. After four weeks, each person either stayed at 2.5 mg or stepped up to 5 mg, a choice made through shared decision-making with their clinicians rather than by chance. Of the 112 people analyzed, 58 stayed at 2.5 mg and 54 moved to 5 mg. The average starting BMI was 30.8 ^[1].

At six months, the study's primary measure, reaching a BMI below 25 or losing more than 15 percent of body weight, was met by 62.1 percent of the 2.5 mg group and 63.0 percent of the 5 mg group (hazard ratio 0.93, 95 percent confidence interval 0.58 to 1.49; p = 0.772). Mean weight loss was 15.3 percent on 2.5 mg and 16.1 percent on 5 mg (p = 0.563). Reductions in BMI, skeletal muscle mass and bone mass were similar between the two groups ^[1].

Adverse events were more common at 5 mg. Half of that group reported them, compared with 35 percent at 2.5 mg, and they were mostly gastrointestinal symptoms. Dietary adherence was 96.4 percent across both groups, while exercise adherence was 37.5 percent ^[1].

The authors note that the design limits how far the findings travel. Because people were not assigned to a dose at random, those who stayed at 2.5 mg may have differed from those who escalated in ways that affect weight, so the study cannot prove the doses themselves caused the similar results. Six months is short for judging a weight-loss treatment, and the cohort was entirely Japanese and unusually consistent about diet. The authors conclude that the findings support the potential utility of low-dose tirzepatide strategies in real-world practice ^[1].

Why it matters for patients

In this study, the two doses produced weight loss that was statistically indistinguishable, while the lower dose came with fewer adverse events. For patients deciding whether to move up a dose after the first month, that is the trade-off the data describe. The study did not compare either dose with maintenance doses above 5 mg, so it says nothing about how 2.5 mg or 5 mg compares with higher ones ^[1].

The results also do not transfer automatically to U.S. patients. Everyone in the cohort had obesity without diabetes, all were Japanese, and nearly all followed the diet counseling, a level of adherence that may not reflect typical practice. Whether the same pattern would appear in a more mixed population, or in people with type 2 diabetes, has not been reported ^[1].

Because dose assignment was a shared decision rather than randomization, the study cannot separate the effect of the drug dose from the characteristics of the people who chose it. It also does not report what happened to participants after the six-month mark, and it offers no evidence about how to choose a dose for any individual patient ^[1].

What happens next

The paper appears in the journal's October 2026 issue, volume 28, issue 10, pages 9395 to 9402, and was first published online July 28, 2026 ^[1]. The authors state that the underlying data are available from the corresponding author on request and that the peer review history is posted online. The article does not describe a randomized trial of low-dose maintenance or longer follow-up; no such study is announced in the paper, and the authors declare no conflicts of interest ^[1].